PreciMune

PreciMune is a service platform offering as first product, SEQTR (SEQuencing T-cell Receptor), a high-resolution and accurate TCR sequencing assay with the ultimate goal to address the urgent need for predictive and early-response biomarkers in cancer immunotherapy. By profiling the T cell receptor (TCR) repertoire, SEQTR enables clinicians to identify patients most likely to benefit from treatment and monitor their response early on. IP-protected and in the process of being clinically validated in collaboration with leading cancer centers, SEQTR is positioned to become a key decision-support tool in the precision oncology landscape.